CHESTER, N.J., Oct. 26 /PRNewswire-FirstCall/ -- Adams Respiratory Therapeutics, Inc. today announced that the Healthcare Distribution Management Association (HDMA) recognized Mucinex(R) D with its desirable “DIANA” award during its Annual Leadership Forum held Oct. 4-6, 2006, in Orlando, Fla. Mucinex(R) D was the only over-the-counter, or OTC, product to receive such recognition at this year’s event.
Mucinex(R) D is the only FDA-approved extended-release guaifenesin-based combination tablet (600 mg guaifenesin/60 mg pseudoephedrine HCl) that provides relief of chest and nasal congestion and sinus pressure due to colds or allergies with convenient 12-hour dosing. Launched about one year ago in October 2005, Mucinex(R) D was supported by its own advertising starting in February 2006 to target sufferers of congested allergies. As a result of the combined efforts of our trade, sales and marketing teams, Mucinex(R) D has achieved solid trade distribution and retail consumption.
The DIANA (Distribution Industry Award for Notable Achievements in Health Care) award has long been a prestigious honor at HDMA, an organization for wholesaler drug accounts and healthcare distributors. The award winner is chosen by HDMA’s members based on sales and market share achieved, overall category sales impact, and the quality and impact of marketing support programs.
Bill Fogarty, Adams’ senior vice president, sales and trade development, accepted the award.
About Adams Respiratory Therapeutics, Inc.
Adams is a specialty pharmaceutical company focused on the late-stage development, commercialization and marketing of over-the-counter and prescription pharmaceuticals for the treatment of respiratory disorders.
Adams Respiratory Therapeutics, Inc.
CONTACT: Investor/Media, Janet M. Barth of Adams Respiratory Therapeutics,Inc., +1-908-879-2428
Web site: http://www.adamsrt.com/
